Instrumental Variable Methods to Assess Quality of Care

INTRODUCTION
In randomized studies of process improvement interventions, the average effect of 124 the total process improvement package is validly estimated through intention-to-treat analyses. However, it is often desirable to know the contribution of each individual 126 process in the package to the outcomes achieved. As long as the providers who are 127 delivering the intervention have discretion in the types or level of processes to deliver, 128 there is an opportunity to evaluate how this variability relates to outcomes.
129
The confounding problem intrinsic to as-treated analyses of such "randomized 130 process studies with discretion" can be alleviated using instrumental variable (IV) 131 estimators. 12, 13 IV estimators use randomization as the "instrument" to exploit only the 132 process change related to randomization when assessing the effects of process on 133 outcomes. However, when employing this IV approach using a single randomized study,
134
it is only possible to assess the effects of a single process measure. This study tried to 
METHODS
150
Data and study period 151 The data were obtained from two prospective, cluster randomized controlled 152 clinical trials, namely trial A in 2009 11 and trial B in 2008 15 by Carter and colleagues.
153
Further description of the studies has been published previously. 11, 15 Both trials examined showed that the variability in the intervention effects between the two studies was likely 160 to be due to chance alone (Appendix B).
161
Trial A implemented a 6-month collaborative intervention whereas trial B 162 implemented a 9-month intervention and measured BP at six months. For consistency this 163 study evaluated 6 months of data from both trials. The number of subjects was slightly 164 different from the totals across the original trials because the subjects included in this 165 study were required to complete 6 months in their respective study to provide healthcare 166 utilization data to estimate treatment costs.
167
The use of 6-month data of trial B implementing the 9-month intervention is 168 valid because the process of care mostly occurred in the first few months and BP
169
outcomes at six months and those at nine months were similar. In trial B, the vast 
288
The discretion available to providers in the in the trials to initiate counseling relationships between processes and BP reductions will be biased low and the 295 relationships between the processes and healthcare costs will be biased high.
296
To address bias caused by unmeasured confounders driven by discretion, IV 297 methods were utilized. IV methods provide an alternative approach to addressing 298 problems with unmeasured confounders by using "instruments" to isolate the variation in 299 the processes of care that is not associated with unmeasured confounders. 13, 28 Instruments 300 are measured variables that must be correlated with process of care (instrument relevance To identify distinct process effects, the number of instruments in an IV study must 308 be greater than or equal to the number of processes being analyzed and the instruments 309 must have independent effects on each process. 28, 30 The second condition is needed were calculated to help assess the extent that the property of exogeneity held here.
337
The IV models were estimated using two-stage least squares (2SLS 
365
As a comparison, ordinary-least-squares (OLS) linear regression models were 366 utilized to estimate the effects of the processes on outcomes using an as-treated approach.
367
The outcome model was explained by number of counseling sessions about lifestyle 368 modification, number of specified-dose antihypertensive medications, and the control 369 variables.
370
For consistency, linear specification was used for both as-treated and IV models.
371
In addition, robust standard errors were estimated throughout because the distribution of 372 the error terms across observations was unknown. respectively. To explain subjects excluded from the pool of subjects from trials A and B
389
due to the requirement of complete 6-month data, there were 85 excluded subjects and 390 51% were female. The average age was 53 years and 60% of them were white/Caucasian.
391
Although the excluded subjects were relatively younger than the included subjects, the reject the null hypothesis (p-value = 0.50), suggesting that the fully-specified IV models 
454
Each fully-specified IV model ( 
458
In each fully-specified IV model insufficient variation was available from each predicted 459 process to accurately assess the effect of each process on outcomes.
461
Post-hoc IV analysis
462
The results from post-hoc IV models ( DBP change that were biased low and effects on total cost that were biased high.
486
When utilizing fully-specified IV models to address unmeasured confounders, the 487 models were unidentified. Even though the instruments significantly explained the though the interventions differed between trials, these differences were unable to generate 492 sufficient differences in how the two processes were offered to patients across the studies.
493
In the post-hoc IV models, however, both process measures were associated with 494 reductions in SBP, and DBP and increased total costs. These estimates are potentially estimates relative to the fully-specified IV models, the confidence intervals around the 500 post-hoc IV estimates provide a defensible range for the true parameter values.
501
The signs of the estimates from the post-hoc IV models and the as-treated models control. 9 Their observational study using a sample from eight general practices in the
511
United Kingdom found that three or more BP lowering drugs (vs. one drug) was not 512 associated with BP control (adjusted odds ratio = 1.31, 95% CI = 0.96 to 1.79). This was 513 similar to the present study whereby the association between BP reduction and number of 514 specified-dose antihypertensive agents from the as-treated models was not found. This 515 finding is likely due to the fact that subjects with the most difficult to control BP required 516 more medications and yet, had less of an effect on BP.
517
In addition, Inkster and colleagues found that a higher number of consultations of the process effects on costs. 13 Using the data from a randomized controlled trial, their 527 study evaluated the impact of the evidence-based acute pain management practices on 528 inpatient cost changes. The estimate from the IV methods showed that such practices 529 resulted in a drop of inpatient costs by $1,602, which was largely greater than the 530 estimate of the inpatient cost reduction by $58 by using as-treated methods.
531
The following limitations of this study are acknowledged. Considerable 532 differences in baseline characteristics remained between the groups of patients divided by 533 the instruments according to Table 1 instruments and the control variables, the IV estimates will be biased low. Likewise, if 539 those correlations have the same direction, the IV estimates will be biased high.
540
As stated earlier, the present study was unable to estimate the individual effect of 
APPENDIX A: BASELINE CHARACTERISTICS ACROSS TRIALS
